CSF/plasma HIV-1 RNA discordance even at low levels is associated with up-regulation of host inflammatory mediators in CSF by Nightingale, Sam et al.
Cytokine 83 (2016) 139–146Contents lists available at ScienceDirect
Cytokine
journal homepage: www.journals .e lsev ier .com/cytokineCSF/plasma HIV-1 RNA discordance even at low levels is associated
with up-regulation of host inflammatory mediators in CSFqhttp://dx.doi.org/10.1016/j.cyto.2016.04.004
1043-4666/ 2016 Published by Elsevier Ltd.
q Data presented at BHIVA autumn conference, Brighton, 23/04/2015.
⇑ Corresponding author at: The Ronald Ross Building, 8 West Derby Street, University of Liverpool, L69 7BE, UK.
E-mail address: s.nightingale@liv.ac.uk (S. Nightingale).Sam Nightingale a,b,c,⇑, Benedict D. Michael a,d, Martin Fisher e, Alan Winston f, Mark Nelson g,
Steven Taylor h, Andrew Ustianowski i, Jonathan Ainsworth j, Richard Gilson k, Lewis Haddow k,
Edmund Ong l, Clifford Leenm, Jane Minton n, Frank Post o, Apostolos Beloukas a, Ray Borrow p,
Munir Pirmohamed b, Anna Maria Geretti a, Saye Khoo b, Tom Solomon a,d
a Institute of Infection and Global Health, University of Liverpool, UK
bDepartment of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK
cRoyal Liverpool and Broadgreen University Hospitals NHS Trust, UK
dWalton Centre for Neurology and Neurosurgery, Liverpool, UK
eBrighton and Sussex University Hospitals NHS Trust, UK
f St Marys’ Hospital, Imperial College Heathcare NHS Trust, London, UK
g St Stephen’s AIDS Research Trust and Chelsea and Westminster Hospital NHS Foundation Trust, UK
hBirmingham Heartlands Hospital, Heart of England NHS Foundation Trust, UK
iNorth Manchester General Hospital, Pennine Acute Hospitals NHS Trust, UK
jNorth Middlesex University Hospital NHS Trust, UK
kResearch Department of Infection and Population Health, University College London, UK
lVictoria Royal Infirmary, Newcastle upon Tyne Hospitals NHS Trust, UK
mRoyal Infirmary of Edinburgh, NHS Lothian, UK
n Leeds General Infirmary, Leeds Teaching Hosptials NHS Trust, UK
oKings College Hospital NHS Foundation Trust, London, UK
pVaccine Evaluation Unit at the Health Protection Agency (HPA) North West, Manchester, UKa r t i c l e i n f o
Article history:
Received 3 February 2016
Received in revised form 4 April 2016
Accepted 5 April 2016
Available online 28 April 2016
Keywords:
HIV
Cerebrospinal fluid
CSF escape
Sanctuary site
Inflammationa b s t r a c t
Introduction: HIV-1 RNA can be found at higher levels in cerebrospinal fluid (CSF) than in plasma, termed
CSF/plasma discordance. The clinical significance of CSF/plasma discordance is not known and the degree
of discordance considered important varies. We aimed to determine whether a panel of CSF cytokines,
chemokines and associated mediators were raised in patients with CSF/plasma discordance at different
levels.
Methods: A nested case-control study of 40 CSF samples from the PARTITION study. We used a cytometric
bead array to measure CSF mediator concentrations in 19 discordant and 21 non-discordant samples
matched for plasma HIV-1 RNA. Discordant samples were subdivided into ‘high discordance’ (>1log10)
and ‘low discordance’ (0.5–1log10, or ultrasensitive discordance). CSF mediators significant in univariate
analysis went forward to two-way unsupervised hierarchical clustering based on the patterns of relative
mediator concentrations.
Results: In univariate analysis 19 of 21 CSF mediators were significantly higher in discordant than non-
discordant samples. There were no significant differences between samples with high versus low discor-
dance. The samples grouped into two clusters which corresponded to CSF/plasma discordance
(p < 0.0001). In cluster one all mediators had relatively high abundance; this included 18 discordant sam-
ples and three non-discordant samples. In cluster two all mediators had relatively low abundance; this
included 18 non-discordant samples and one non-discordant sample with ultrasensitive discordance only.
Conclusions: CSF/plasma discordance is associatedwith potentially damaging neuroinflammatory process.
Patients with discordance at lower levels (ie. 0.5–1log10) should also be investigated as mediator profiles
were similar to those with discordance >1log10. Sensitive testing may have a role to determine whether
ultrasensitive discordance is present in those with low level CSF escape.
 2016 Published by Elsevier Ltd.
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For some patients with human immunodeficiency virus (HIV)
viral ribonucleic acid (RNA) is at higher levels in cerebrospinal fluid
(CSF) than plasma [1,2]. This phenomenon, termed CSF/plasma dis-
cordance, can occur in approximately 10% of individuals with HIV
undergoing a lumbar puncture in clinical practice [1–4]. The causes
and clinical significance of discordance remain to be determined.
Whilst CSF/plasma discordance has been associated with fulmi-
nant central nervous system (CNS) diseases in case series, these
appear to be uncommon in clinical practice [5,6]. Moreover, the
association of CSF/plasma discordance with cognitive impairment
in antiretroviral therapy (ART) treated cohorts is not clear [7–9].
The pathophysiological processes underlying discordance are also
not clear, in particular it is not known if CSF/plasma discordance
is associated with an up-regulation in the host inflammatory
response and at what level of discordance this occurs. Previous
studies have identified up-regulation of several cytokines and asso-
ciated mediators in patients with cognitive decline although this
has not been investigated in discordance [10,11].
There is currently no consensus on the degree of discordance
between CSF and plasma HIV-1 RNA that should be considered
clinically significant. Some studies have defined discordance as
CSF HIV-1 RNA 1log10 greater than the corresponding plasma sam-
ple [5], whilst others have used a lower cut off of 0.5log10 [1]. In
those with unquantifiable HIV-1 RNA in plasma (typically <40 or
<50 copies/ml) some studies have described the detection of CSF
virus at any level above this detection limit as being significant
(termed ‘‘CSF viral escape”) [2], while others have excluded those
with CSF HIV-1 RNA below 200 copies/ml [1,5]. This has led to dif-
ficulties comparing studies as well as confusion in clinical practice
as to what cut-off to use.
Sensitive testing can now detect HIV-1 RNA below the tradi-
tional threshold of 40 or 50 copies/ml. A proportion of patients
have CSF/plasma discordance detected on these assays that would
not otherwise be classified as discordant if tested with standard
assays [3,12]. The source and significance of CSF/plasma discor-
dance at this low level remains controversial [13,14]. Such sensi-
tive testing is currently only available as a research tool, however
assays with a lower limit of quantification of 20 copies/ml are
now being used routinely in many clinical centres and conse-
quently CSF/plasma discordance below 50 copies/ml is an increas-
ingly recognised phenomenon in clinical practice.
This nested case-control study aimed to assess whether
CSF/plasma discordance was associated with cytokines, chemoki-
nes and accompanying mediators in the CSF, when compared with
non-discordant samples. Furthermore we aimed to examine the
relationship between CSF mediator profile and degree of
CSF/plasma discordance to determine whether discordance at
lower levels (ie levels that have been excluded in some published
studies) are associated with potentially damaging CNS
inflammation.2. Methods
2.1. Study population
Patients were recruited prospectively through the PARTITION
study, which is a multicentre UK study described elsewhere [15].
HIV-1 positive ART treated adults were recruited in two groups:
113 patients undergoing lumbar puncture for a clinical indication
of which 92 (81%) had no evidence of CNS infection (clinical group),
and 40 patients undergoing research lumbar puncture to investi-
gate intermittent or persistent plasma HIV-1 RNA detection (low
level viraemia (LLV) group). In this group median HIV-1 RNA levelsduring viraemic episodes was 92 copies/ml (IQR 59, 179). A ran-
domly selected subgroup with unquantifiable plasma HIV-1 RNA
on the standard testing (ie. <40 copies/ml) underwent sensitive
HIV-1 RNA detection with a modified Abbott assay with a lower
limit of detection of 1–10 copies/ml dependent on volume tested
[15].
Patients in the LLV group underwent a brief cognitive screen
using the International HIV Dementia scale [16], and were assessed
for symptoms of cognitive impairment using the three standard
questions described by Simioni et al. [17]. A score of less than
ten on the HIV dementia scale was considered abnormal and a
patients were considered to have cognitive symptoms when
answering ‘‘yes, definitely” on at least one of the three questions.
2.2. Laboratory assessment
CSF cell count, protein and glucose measurements, microbiolog-
ical investigations, and CD4 cell counts were performed by routine
methods at the centres of care. As lumbar puncture was performed
for research purposes in the LLV group, local CSF testing was only
performed in this group if considered clinically indicated by the
treating physician. HIV-1 RNA was measured centrally in simulta-
neous plasma and CSF samples by the Abbott RealTime HIV-1 assay
(Maidenhead, UK) with a lower limit of quantification of 40 copies/
ml, as previously described [18].
2.3. Selection criteria
Discordant samples were selected from the clinical and LLV
groups. In the clinical group patients with CNS infection were
excluded. Discordance was defined as CSF HIV-1 RNA >0.5log10
times that measured in a simultaneous plasma sample. In those
with unquantifiable plasma HIV-1 RNA, discordance was defined
as a CSF HIV-1 RNA >0.5log10 times the lower limit of assay quan-
tification (ie. 40 copies/ml). Samples were categorised as ‘‘high dis-
cordance” if CSF HIV-1 RNA was >1log10 times that of plasma and
‘‘low discordance” if the ratio was 0.5–1log10. Samples with discor-
dance only detected on sensitive assay were termed ‘ultrasensitive
discordance’ and analysed within the low discordant group.
For controls, we screened all participants in the PARTITION
study who did not have discordance, and selected those with a
plasma HIV-1 RNA which most closely matched that of samples
with discordance. Those with the lowest CSF HIV-1 RNA were
selected.
CSF viral escape was defined as plasma HIV-1 RNA less than the
lower limit of quantification for the standard assay (ie 40 copies/
ml), and CSF P40 copies/ml.
2.4. Measurement of mediators
CSF was collected at recruitment and centrifuged to remove
cells. Samples were stored at 70 C and freeze thaw cycles min-
imised. Thirty-seven mediators (cytokines, chemokines and associ-
ated mediators) were assessed using a cytometric bead array assay
system in accordance with the manufacturers’ instructions
(Procarta  Immunoassay kit, Panomic Solutions, Affymetrix 
Milano, Italy. The mediators assessed were chosen from reviewing
previous literature: granulocyte-colony stimulating factor [G-CSF],
granulocyte-macrophage-colony stimulating factor [GM-CSF],
myeloperoxidase [MPO], CCL2 [monocyte chemotactant protein
1], CCL3 [C-C motif ligand 3, monocyte inflammatory protein 1a],
CCL4, CCL5 [regulated on activation normal T cell expressed and
secreted- RANTES], CXCL10 [inducible protein 10], vascular cell
adhesion molecule [VCAM], intracellular adhesion molecule
[ICAM], vascular endothelial growth factor [VEGF]a, and matrix
metalloproteinases [MMP] 1, 2, 3, 7, 8, 9, 12 and 13, interferon
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tors [TNFR1 and TNFR2] and TNFa-related apoptosis inducing
ligand [TRAIL], interleukin [IL] 1a, 1b, 2, 4, 6, 8, 10 and 17a,
IL17f, and IL1-receptor antagonist [IL1RA]. Analytes were assessed
for all patient groups on one plate for MMPs and one plate for all
other mediators. Fluorescence intensity was determined using a
Bio-Rad platform (BioPlex Manager 4.1, Bio-Rad Laboratories ,
Hertfordshire, UK). Standards and samples were analysed in dupli-
cate and the mean value used in analysis. Standard curves were
adjusted at the points of fluorescence intensity saturation, to gen-
erate a sigmoid standard curve with 6–8 fluorescence intensity
points. To avoid undetectable levels of mediators or missing data
biasing the analysis, only mediators that were detected in at least
80% of the cohort were included in the analyses [19,20].
2.5. Univariate statistical analysis
Clinical and demographic variables were compared by the
Mann-Whitney U test if continuous and by Chi squared or Fisher’s
exact test if categorical. Median concentrations between groups
were compared with the Mann-Whitney U test. Within cases,
individual CSF mediator concentrations were correlated with CSF
HIV-1 RNA using Spearman’s r.
2.6. Two-way unsupervised multivariate analysis
CSF mediators significantly (p < 0.05) associated with
CSF/plasma discordance in univariate analysis were included in a
2-way unsupervised hierarchical cluster analysis based on the pat-
terns of relative mediator concentrations. This offered an opportu-
nity to examine the interactions of mediators and allow samples to
be classified by their overall host mediator response. Samples and
then mediators were hierarchically clustered using the program
Cluster (version 3.0), using the uncentered correlation score as
the similarity metric and the average branch linkage method.
Results were viewed as heat-maps using Tree View software
(http://rana.lbl.gov/EisenSoftware.htm) as described previously
[19,21].3. Results
3.1. Subject characteristics
Of 153 patients recruited in PARTITION, 40 CSF samples were
analysed by cytometric bead array. Nineteen episodes of
CSF/plasma discordance were identified in 18 patients (one subject
had two discordant results in CSF collected at an interval of more
than two years). Eleven (58%) had high discordance and eightNon-discordant samples
(n=21)
Discordant samples
(n=19)
Low discordance
(ie. Excluded in some studies) 
(n=8)
High discordance:
>1log10 on standard assay 
(n=11)
0.5-1log10 on 
standard assay 
(n=5)
Ultrasensitive discordance: 
>0.5log10 on sensitive assay
(n=3)
Fig. 1. Flow-chart of groups described in analysis.(42%) had low discordance; of which three had ultrasensitive
discordance – plasma/CSF HIV-1 RNA 4/40, <7/74 and <10/51
copies/ml (Fig. 1). Median HIV-1 RNA in plasma was <40 copies/
ml (IQR <40, 52) and in CSF was median 422 copies/ml (IQR 138,
1981). Twenty-one non-discordant samples in 21 patients were
selected, matched for plasma HIV-1 RNA. Nineteen (90%) had CSF
HIV-1 RNA <40 copies/ml. Twelve (57%) had low CSF HIV-1 RNA
demonstrated on sensitive assay; median <7 copies/ml (IQR <3,
<7) Two samples had CSF detection not meeting criteria for discor-
dance (plasma/CSF HIV-1 RNA <40/69 and 135/64 copies/ml
(Fig. 2).
Demographic, clinical and laboratory parameters were similar
between discordant and non-discordant samples although discor-
dant patients tended to have a lower nadir CD4 (Table 1). Two of
eight discordant patients in the LLV group had cognitive symp-
toms, one of which had an abnormal HIV dementia scale result.
Three non-discordant patients in the LLV group had cognitive
symptoms, none of which had abnormal HIV dementia scale
results. Median CSF white cell count in the discordant group was
4 cells/ll (IQR <1, 17) and in the non-discordant group was
<1 cell/ll (IQR <1, 1), p = 0.003. CSF white cell count was measured
in 15 discordant samples, of which eight (53%) had <5 cells/ll (ie.
at a level commonly considered to be normal in clinical practice)
and five (33%) had <1 cell/ll. All samples in the non-discordant
group had <5 cells/ll and 14 (74%) had <1 cell/ll.3.2. Univariate analysis of CSF mediators
In over 80% of samples the following mediators had measure-
ments at or below the lower limit of quantification and hence were
excluded from further analysis: GCSF, GM-CSF, IFNa2, IFNb, IL17a,
IL17f, IL2, IL4, TNFa, VEGFa, MMP1, 3, 8, 9, 12 and 13. Nineteen
(90%) of the remaining 21 CSF mediators were significantly higher
in discordant than non-discordant samples (Table 2). This included
interleukins IL-1a/b, IL-6, IL-8 and IL-10, the chemotactic CC
chemokines CCL3, 4 and 5, the TNFa related proteins TNFR1, TNFR2
and TRAIL and adhesion molecules VCAM and ICAM. There were no
significant differences between CSF mediator concentrations in
samples with high versus low discordance (Table 2). There was a
significant correlation between mediator concentrations and CSF
HIV-1 RNA for nine mediators (Table 2); this was strongest for
CXCL10, CCL3, VCAM and TNFR2 (Fig. 3).3.3. Multivariate cluster analysis
The samples grouped into two main clusters based on relative
mediator concentrations; cluster one with higher concentrationsFig. 2. HIV-1 RNA in plasma and CSF in discordant (disc) and non-discordant (non-
disc) groups.
Table 1
Subject characteristics in 19 episodes of CSF/plasma discordance >0.5log10 versus 21 without discordance.
Discordant (n = 19) Non-discordant (n=21) p value
Age, median years (IQR) 47 (44, 57) 47 (41, 53) 0.577
Gender male, n (%) 15 (78.9) 15 (71.4) 1.00
Ethnicity, n (%) 0.408
White MSM 8 (42.1) 12 (57.1)
Black heterosexual 6 (31.6) 3 (14.3)
Other 5 (26.3) 6 (28.6)
CD4
Current, median cells/ll (IQR) 380 (319, 490) 464 (359, 741) 0.189
Nadir, median cells/ll (IQR) 31 (27, 79) 112 (34, 283) 0.102
Time since HIV diagnosis, median years (IQR) 13.0 (9.3, 18.0) 8.0 (4.5, 16.5) 0.087
ART at sampling, n (%) 0.306
PI/r 17 (89.5) 13 (61.9)
NNRTI 2 (10.5) 7 (33.3)
NRTI 17 (89.5) 18 (85.7)
RAL 5 (26.3) 2 (9.5)
MVC 2 (10.5) 3 (14.3)
CPE score (2010), median (IQR) 7 (7, 8) 7 (6, 9) 0.903
Self reported adherence <95%, n (%) 2 (10.5) 2 (9.5) 1.00
Indication for LP, n (%) 0.139
Research LP (LLV group) 8 (42.1) 8 (38.1)
Cognitive symptoms 5 (26.3) 2 (9.5)
Headache 0 (0.0) 3 (14.3)
Suspected CNS infection 1 (5.3) 2 (9.5)
Follow up previous CNS infectiona 3 (15.8) 0 (0.0)
Abnormal neurological exam 1 (5.3) 4 (19.0)
Other 1 (5.3) 2 (9.5)
a CNS toxoplasmosis, EBV encephalitis and VZV encephalitis. IQR, interquartile range; MSM, men who have sex with men; IVDU, intravenous drug user; LP, lumbar
puncture; CNS, central nervous system; CSF, cerebrospinal fluid; CPE, CNS penetration effectiveness score (2010); ART, antiretroviral therapy; PI/r, ritonavir boosted protease
inhibitor; NNRTI, non nucleoside reverse transcriptase inhibitor; RAL, raltegravir; MVC, maraviroc; RNA, ribonucleic acid.
Table 2
Relationship of mediator concentrations between groups and correlation with CSF HIV-1 RNA.
All subjects Discordant subjects Correlation with CSF
HIV-1 RNA
Discordant (n = 19) Non-discordant (n = 21) p value Low discordant (n = 8) High discordant (n = 11) p value Spearman r p value
CCL2 1271 (872.8, 1582) 944.5 (792.9, 1322) 0.305 1139 (691.6, 1562) 1271 (878.8, 1678.0) 0.753 0.284 0.240
CCL3 74.5 (58.0, 128.0) 36.8 (30.8, 39.6) <0.001 63.0 (46.6, 150.8) 92.0 (66.5, 128.0) 0.265 0.597 0.007
CCL4 23.5 (16.0, 59.0) 14.5 (13.0, 18.8) 0.004 17.8 (15.3, 48.9) 26.5 (22.5, 66.5) 0.201 0.506 0.027
CCL5 57.5 (25.0, 190.5) 14.5 (11.5, 22.3) <0.001 33.8 (22.1, 157.3) 85.8 (31.5, 281.5) 0.282 0.523 0.022
CXCL10 6553 (4058, 7342) 1249 (812.8, 2114) <0.001 5136 (3067, 7260) 7038 (4439, 7480) 0.232 0.534 0.019
ICAM 296.0 (176.8, 622.5) 71.5 (62.3, 93.8) <0.001 286.0 (161.2, 525.7) 325.0 (204.0, 774.0) 0.528 0.449 0.054
IFNy 40.0 (32.0, 48.3) 29.5 (24.5, 34.9) 0.001 39.9 (32.1, 46.1) 41.5 (32.0, 53.3) 0.762 0.233 0.338
IL10 26.5 (22.5, 33.0) 17.5 (16.5, 19.5) <0.001 25.8 (21.3, 28.1) 31.0 (22.5, 37.8) 0.455 0.471 0.042
IL1a 53.0 (39.8, 62.0) 20.5 (18.0, 30.3) <0.001 47.1 (36.6, 60.9) 53.0 (43.5, 63.0) 0.362 0.478 0.038
IL1b 9.0 (8.0, 11.0) 7.0 (7.0, 7.8) <0.001 8.8 (8.0, 9.9) 9.5 (8.0, 14.5) 0.453 0.269 0.265
IL1RA 15.0 (13.8, 17.5) 13.5 (12.5, 14.0) 0.001 15.0 (13.5, 15.5) 16.0 (14.3, 24.8) 0.264 0.348 0.144
IL6 9.0 (8.0, 10.5) 7.3 (6.6, 8.3) 0.005 8.5 (7.9, 10.8) 9.0 (7.9, 10.5) 0.953 0.219 0.367
IL8 125.5 (96.0, 169.5) 63.0 (53.0, 79.4) <0.001 119.4 (79.9, 145.4) 128.5 (104.0, 117.3) 0.636 0.322 0.179
MMP2 1234 (959.6, 1335) 941.4 (757.7, 1154) 0.014 1186 (910.6, 1308) 1263 (959.6, 1485) 0.429 0.437 0.061
MMP7 35.1 (26.7, 46.0) 34.1 (22.1, 39.5) 0.634 34.8 (28.8, 43.7) 35.5 (25.7, 46.9) 0.954 0.265 0.272
MPO 23.0 (17.5, 67.8) 16.0 (13.0, 17.6) 0.001 21.6 (16.4, 27.8) 29.5 (21.3, 117.0) 0.134 0.414 0.078
TGFb 82.8 (65.5, 99.8) 55.0 (47.0, 65.1) 0.003 91.9 (68.6, 134.1) 82.8 (64.0, 94.0) 0.236 0.097 0.692
TNFR1 11,788 (8992, 14,874) 7761 (7461, 9346) 0.001 11,267 (9256, 13,491) 11,788 (8444, 18,161) 0.636 0.424 0.071
TNFR2 3131 (2195, 4891) 1032 (815.8, 1402) <0.001 2477 (2159, 4492) 3514 (2526, 7629) 0.302 0.572 0.011
TRAIL 42.5 (36.5, 51.5) 26.9 (29.4, 31.8) <0.001 40.3 (35.4, 46.3) 45.3 (37.3, 52.0) 0.341 0.480 0.038
VCAM 5263 (4458, 5935) 2222 (2831, 3629) <0.001 4995 (4400, 5452) 5508 (4835, 7190) 0.232 0.579 0.009
Nineteen of 21 CSF mediators were significantly (p < 0.05) higher in discordant than non-discordant subject in univariate analysis. There were no significant differences
between CSF mediator concentrations in samples with high (CSF HIV-1 RNA >1log10 plasma) versus low (0.5–1log10 plasma or ultrasensitive discordance) discordance
(Table 2). Nine CSF mediator concentrations correlated with CSF HIV-1 RNA.
CSF, cerebrospinal fluid; RNA, ribonucleic acid. Values are median pg/ll (IQR). P values are by Mann-Whitney-U or Spearman r correlation.
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tained 21 samples, of which 18 (86%) were discordant. Cluster two
contained 19 samples of which 18 (95%) were non-discordant
(p < 0.0001). Grouped in cluster one were all samples with CSF
HIV-1 RNA >1log10 plasma, all with CSF HIV-1 RNA 0.5–1log10
plasma, and two of the three with ultrasensitive discordance. Thesingle discordant sample in cluster two had ultrasensitive discor-
dance (Plasma HIV-1 RNA <7 copies/ml, CSF 74). Two of the three
samples with CSF viral escape not meeting criteria for CSF/plasma
discordance were in cluster two.
The 19 CSF mediators that were found to be significantly
up-regulated in discordant samples in the univariate analysis
Fig. 3. Relationship of CXCL10, CCL3, VCAM and TNFR2 concentration between groups. CXCL10, CCL3, VCAM and TNFR2 concentration (Fig. 1a–d respectively) were
significantly higher in discordant versus non-discordant samples. No significant differences were observed between samples with high (CSF >1log10 plasma) versus low (CSF
0.5–1log10 plasma or ultrasensitive discordance) degrees of discordance. Samples with ultrasensitive discordance are represented with an open circle. Mediator
concentrations correlated with CSF HIV-1 RNA (Fig. 1e–h). Non-disc, non-discordant; Low-disc, low-discordant; High-disc, high-discordant; ns, not significant; CXCL10,
inducible protein 10; VCAM, vascular cell adhesion molecule; CCL3, monocyte inflammatory protein 1a; TNFR2, tumour necrosis factor receptor 2.
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Fig. 4. A heat map displaying the relative concentration of 19 mediators in samples with and without CSF/plasma discordance. Samples and mediators were organised via an
unsupervised hierarchical clustering algorithm along the horizontal and vertical axes respectively. Twenty-one samples without discordance are labeled on the x-axis with
the symbol ‘‘o”. Nineteen samples with discordance are indicated by the symbol ‘‘+”; discordant samples with CSF HIV-1 RNA >1log10 plasma are labeled ‘‘+++” (n = 11), CSF
0.5–1log10 plasma are labeled ‘‘++” (n = 5) and those with ultrasensitive discordance are labeled ‘‘+” (n = 3). Tile colour indicates relative mediator concentration: red,
increased; green, decreased; black, at median concentration (for the samples). On the horizontal axis the samples segregated into two main clusters, cluster one and two,
corresponding significantly to discordant and non-discordant samples respectively (p < 0.0001). Grouped in cluster one were all samples with CSF HIV-1 RNA >1log10 plasma,
all with CSF HIV-1 RNA 0.5–1log10 plasma, and two of the three with ultrasensitive discordance. One subject with ultrasensitive discordance (CSF HIV-1 RNA 74, plasma <7
copies/ml) was grouped in cluster two. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
144 S. Nightingale et al. / Cytokine 83 (2016) 139–146clustered into two main sets (Fig. 4). The first set included IL1b, IL6,
IL10, TRAIL and MPO; the second set included TGFb, CCL3, CCL4,
CXCL10, IL1a, IL8, VCAM, ICAM, IFNc, TNFRI and II. Three media-
tors (IL1RA, CCL5 and MMP2) were outlying these sets.4. Discussion
In patients receiving ART, the clinical significance of CSF/plasma
HIV-1 RNA discordance is poorly understood, and the relevance of
low levels of discordance has not been assessed. This study found
that CSF/plasma discordance was associated with the increased
expression of host inflammatory mediators in the CSF in compar-
ison to non-discordant patients. Moreover, there was no significant
difference in the concentration of these mediators between
patients with high and low level discordance. In addition, the
mediator profiles clustered cases with both high and low discor-
dance together and were distinct from the non-discordant patients.
Taken together these findings suggest that discordance of HIV is
the CSF is associated with a potentially deleterious host inflamma-
tory response and may therefore be of significance, and that this
may have implications for patients even with low levels of discor-
dance. Longitudinal studies assessing these mediators and CSF
HIV-1 RNA in conjunction with clinical outcomes are needed to
better elucidate the temporal relationship between discordance,
host inflammatory response, and clinical outcomes. In addition,
more work is needed to examine whether discordance could be a
result of an inflammatory process, rather than the cause of it.
Whether the neuroinflammation observed in association with
discordance led to adverse clinical outcomes in this study is not
clear. Neurological symptoms occurred both in those with and
without discordance in both groups. Just one patient in the LLV
group had an abnormal cognitive screen, however this is an insen-
sitive test for milder forms of cognitive impairment. Cognitive
function in HIV positive cohorts is highly variable and impairment
is multifactorial, hence to identify insidious neurological damagerelated to long-term low-grade neuroinflammation would require
larger cohorts and more detailed cognitive testing than was per-
formed in our study [22]. In other studies raised CSF concentra-
tions of many of these mediators have been shown to correlate
with HIV-associated neurocognitive disorders, althoughmost stud-
ies were in the pre/early-combination ART era. This subject has
been reviewed extensively by Brew and Letendre [7]. So far no sin-
gle mediator has been shown to have a sufficiently strong correla-
tion with cognitive status to be a clinically useful biomarker and a
combination of biomarkers may be more useful [10].
Surprisingly we did not find an association of CCL2 (MCP-1)
with discordance. This chemokine is associated with chemotaxis
of monocytes across the blood-brain barrier and has been associ-
ated with cognitive impairment in HIV positive populations in
the pre and post-combination ART era [23]. The reasons why we
found no association are unclear, but in one study higher concen-
trations of CCL2 were associated with both better and worse cogni-
tive outcomes dependent on the relative concentration of other
mediators, including TNFRII, and additional parameters, including
nadir CD4 [10], highlighting the complex interaction of the host
inflammatory response and other viral and host factors. We also
expected to see an association of discordance with TNFa as CSF
levels have been associated with brain injury and TNFa mRNA
levels are elevated in the brain tissue of cognitively impaired HIV
infected patients [24]. >80% of TNFa measurements were below
the limit of quantification in our analysis, however levels of all
three closely related proteins TNFR1, 2 and TRAIL were associated
with discordance. CSF pleocytosis was more frequent in the discor-
dant group, consistent with the hypothesis that discordance is
associated with CNS inflammation. Of note half did not have a
CSF pleocytosis and a third had no measurable white cells in CSF,
suggesting that CSF white cell count alone may not be a sensitive
biomarker of neuroinflammation.
Samples with higher degrees of CSF/plasma discordance tended
to have higher CSF mediator concentrations. This effect was not
strong and the difference between low and high discordant groups
S. Nightingale et al. / Cytokine 83 (2016) 139–146 145was not statistically significant for any single mediator. This is con-
sistent with data from the CNS HIV Antiretroviral Therapy Effects
Research (CHARTER) study, the largest cohort in this area, which
found that although the absolute level of CSF HIV-1 RNA was not
related to cognitive performance, the presence of discordant virus
was [3].
When taken together the majority of samples with low CSF dis-
cordance had raised CSF mediator concentrations clustered in a
similar pattern to those with high discordance. Only one low
discordant subject had low CSF mediator concentrations and was
grouped with the non-discordant cluster. Our data suggests that
the criteria for CSF/plasma discordance used in some studies (ie.
those excluding patients with <1log10 difference and/or
<200 copies/ml in CSF) may risk type two error, and the use of
these criteria in clinical practice risks missing patients with a
potentially significant host inflammatory response [1,5]. Our data
suggest that the lower cut-off of 0.5log10 should be considered.
This is consistent with our previous work demonstrating drug-
resistant HIV-1 in CSF in patients with 0.5–1log10 discordance
and <200 copies/ml in CSF [15].
Reports have suggested that CSF HIV-1 RNA detection at levels
below 50 copies/ml may be associated with cognitive impairment
[3,12]. In this study, two of the three samples with ultrasensitive
discordance had raised CSF mediator profiles grouped with other
discordant samples. Although the numbers are small, our data sup-
port the MIND exchange consensus report recommendations that
sensitive HIV-1 RNA testing should be considered in those with
neurological or cognitive symptoms and less than 50 copies/ml in
CSF and plasma [14]. Samples with CSF viral escape not meeting
criteria for CSF/plasma discordance did not consistently have
raised CSF mediator profiles. The definition of CSF viral escape
could theoretically include a subject with 41 copies/ml in CSF
and 39 copies/ml in plasma; such differences are likely to repre-
sent random biological and statistical variation or limitations of
the assay, rather than CNS compartmentalised virus [25]. Of note,
CSF viral escape has not been associated with cognitive impair-
ment in large cross sectional studies [4,26]. Although confirmation
in larger cohorts is needed, our data suggest that patients with CSF
viral escape at levels not meeting criteria for CSF/plasma discor-
dance should be considered for sensitive testing in plasma to
determine the true extent of discordance between the two
compartments.
Some studies have demonstrated no association between CSF
HIV-1 RNA levels and cognitive performance [27]. This may be
due to the multifactorial nature of cognitive impairment in HIV
rather than indicating that CSF HIV-1 detection does not have
potential consequences for the brain [22]. Our data demonstrate
that CSF/plasma discordance is associated with host inflammatory
mediators in the CSF and support performing CSF HIV-1 RNA quan-
tification in clinical practice. Of note the majority of discordant
samples in this study had plasma HIV-1 RNA levels that were
unquantifiable on standard testing and would have been classified
as successfully treated on plasma testing alone. No subject had
plasma HIV-1 RNA above 400 copies/ml, the level associated with
long-term virological failure [25]. CSF discordance, even at low
levels, requires further investigation; the indications for perform-
ing lumbar puncture solely to measure CSF HIV-1 RNA, and strate-
gies for managing those patients found to be discordant, remain an
important topic for future research.5. Conclusion
CSF/plasma HIV-1 RNA discordance is associated with a poten-
tially damaging neuroinflammatory process. Patients with discor-
dance at lower levels (ie. 0.5–1log10) should also be investigatedas mediator profiles were similar to those with discordance
>1log10. Sensitive testing may have a role to determine whether
ultrasensitive discordance is present in those with low level CSF
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